financetom
Business
financetom
/
Business
/
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
Jul 9, 2025 8:52 AM

Shares of Evoke Pharma Inc ( EVOK ) are trading sharply higher Wednesday morning after the specialty pharmaceutical company announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI.

What To Know: The nasal spray is a treatment for adults with moderate to severe symptoms of diabetic gastroparesis. The new patent, which is expected to expire in December 2036, will extend the market exclusivity for GIMOTI®, a non-oral formulation of metoclopramide.

Evoke Pharma ( EVOK ) plans to list the patent in the FDA’s Orange Book, a key move in protecting the drug from generic competition. This news sent the company’s stock price into overdrive, with shares trading significantly higher in Wednesday’s session.

“This new patent allowance adds meaningful value to the GIMOTI® franchise by reinforcing protection around how and in whom the therapy is used,” said Matt D’Onofrio, CEO of Evoke Pharma ( EVOK ).

The company stated this patent strengthens GIMOTI’s position as a critical treatment option for a patient population that often struggles with the effectiveness of traditional pills.

Price Action: According to data from Benzinga Pro, EVOK shares are trading higher by 171.6% to $7.29 Wednesday morning. The stock has a 52-week high of $12.32 and a 52-week low of $1.94.

Read Also: Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

How To Buy EVOK Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Evoke Pharma’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says
Apr 26, 2024
12:24 PM EDT, 04/26/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) is expected to grapple with Q1 seasonality when reporting March quarter results early next month, despite the ongoing Eylea HD launch, Oppenheimer said in a note Thursday. We model a sequential decrease in revenues (-6%) and non-GAAP EPS (-16%) decline, in line with company compiled consensus, Oppenheimer analysts,...
Why Is Research Company Exponent Stock Soaring Today?
Why Is Research Company Exponent Stock Soaring Today?
Apr 26, 2024
Engineering and scientific consulting firm Exponent Inc ( EXPO ) shares are skyrocketing after the company reported better-than-expected first-quarter FY24 earnings. Exponent reported first-quarter FY24 sales growth of 3.3% year-on-year to $144.93 million, beating the analyst consensus estimate of $125.98 million. Exponent’s engineering and other scientific segment represented 84% of the company’s revenues before reimbursements in the first quarter of 2024. Operating income for the...
Keurig Dr Pepper's Coffee Business Could Accelerate Organic Revenue Growth, UBS Says
Keurig Dr Pepper's Coffee Business Could Accelerate Organic Revenue Growth, UBS Says
Apr 26, 2024
12:19 PM EDT, 04/26/2024 (MT Newswires) -- Keurig Dr Pepper ( KDP ) could see accelerating organic revenue growth given its innovation timing, improving underlying category trends in its coffee business, and new and existing partnerships in its coffee and US refreshment beverages businesses, UBS Global Research said in a note. The company reported Q1 adjusted earnings of $0.38 per...
--Street Color: Starbucks, Workers United Union Say 'Significant Progress' Made in Contract Negotiation This Week in Atlanta
--Street Color: Starbucks, Workers United Union Say 'Significant Progress' Made in Contract Negotiation This Week in Atlanta
Apr 26, 2024
12:18 PM EDT, 04/26/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 89.14, Change: +1.30, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved